
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Uncontrolled Asthma : When to step up therapy Dog bites and PTSD : Helping wounded children cope Point-of-care testing : What's right for your practice? Dermcase : A baby with giant freckles? Puzzler : Infant has respiratory distress and weak cry






